{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

Relevance of ARNi, Carvedilol, Ivabradine in Indian Heart Failure patients to Strengthen the Evidence based practice

  1. What are the signs of heart failure? *

  2. What are the common causes of heart failure? *

  3. What can be done to manage heart failure? *

  4. What are the four pillars of Heart Failure (HF)? *

  5. Do you prefer ARNI in HF with resistant hypertension? *

  6. Do you prefer ARNI in heart failure with preserved ejection fraction (HFpEF)? *

  7. Do you prefer ARNI in heart failure with mildly reduced ejection fraction (HFmrEF)? *

  8. What is your preferred method of therapy initiation in HF? *

  9. What is the most commonly used dose of ARNI *

  10. What is the limiting factor to up-titrate dose of ARNI *

  11. NT-proBNP is it preferred as first line screening tool in practice *

  12. Do you prefer ARNI in HF with renal impairment patients *

  13. What percentage of patients achieve the highest dose of ARNI *

  14. Lowering blood pressure significantly reduces cardiovascular morbidity and mortality. *

  15. The European Society of Hypertension/European Society of Cardiology guidelines recommend the use of β-blockers as first-line or second-line antihypertensive agents. *

  16. Which among the following is a 3rd generation β-blocker with additional alpha-blocking activity, used widely for the management of hypertension? *

  17. In contrast to classic β-blockers, carvedilol maintains cardiac output, has a lesser effect on heart rate, and decreases BP mainly by decreasing vascular resistance *

  18. Do you agree that Carvedilol decreases arterial BP to a greater extent than the traditional β-blocker in patients with moderate and essential hypertension? *

  19. β-blocker having vasodilatory properties, Carvedilol, has beneficial effects on glycemic control and insulin sensitivity *

  20. Carvedilol when given in hypertensive patients with type 2 diabetes leads to: *

  21. The risk for new-onset diabetes is lowered in patients receiving Carvedilol. *

  22. Do you agree α-blocking effect of Carvedilol may provide a superior benefit in terms of left-ventricular hypertrophy regression, compared with traditional β-blockers? *

  23. 6 months of daily therapy with Carvedilol 25 mg in elderly patients with essential hypertension and left-ventricular hypertrophy show *

  24. Do you agree Carvedilol exerts a renoprotective effect? *

  25. Addition of Carvedilol to conventional heart failure therapy in mild to moderate CKD patients is beneficial and safe. *

  26. The beneficial effect of carvedilol on kidney function is demonstrated by: *

  27. Do you agree Carvedilol has an excellent tolerability profile across a wide range of patient types, thus improving the potential for compliance? *

  28. Ivabradine is used to treat heart failure. How does it work? *

  29. What makes Ivabradine a good option to treat heart failure? *

  30. The European Society of Cardiology (ESC) recommends the use of ivabradine to- *

  31. The main effect of Ivabradine therapy is the substantial lowering of HR. *

  32. Recently updated HF guidelines recommend Ivabradine as a class II indication for reduction of HF hospitalizations. *

  33. Various regulatory agencies now recommend the use of ivabradine in patients with HR of 70 bpm or higher. *

  34. Oral anticoagulants are broadly utilized for long-term prevention and treatment of venous thromboembolism (VTE). *

  35. Dabigatran is a competitive direct thrombin inhibitor approved by the US FDA for prevention of embolic stroke in patients with nonvalvular atrial fibrillation. *

  36. Benefits of Dabigatran include- *

  37. Clinicians are rapidly prescribing this agent as a replacement for warfarin therapy *

  38. Dabigatran demonstrated a lower risk for intracranial bleeding, compared with warfarin. *

  39. What is considered an appropriate approach in your practice Reaching target dose or adding all molecules with proven mortality benefit? (based on symptoms and signs) *
  40. Which drugs among the present available one’s are preferred as first to be initiated in your practice and why? *